Researchers at the National Autonomous University of Mexico (UNAM) are developing a novel ophthalmic treatment that could fundamentally change how patients manage diabetic retinopathy, one of the leading causes of blindness worldwide. By utilizing a natural molecule called vasoinhibin, the team has designed eye drops that aim to replace the invasive, costly and often grueling regimen of intraocular injections currently required to save patients’ sight.
For millions of people living with diabetes, the threat of vision loss is a constant anxiety. Diabetic retinopathy occurs when chronically high blood sugar levels damage the delicate blood vessels of the retina—the light-sensitive tissue at the back of the eye. As these vessels leak or close, the body attempts to compensate by growing fresh, fragile blood vessels in a process known as angiogenesis. While this sounds helpful, these new vessels are poorly formed and prone to leaking fluid and blood into the retina, causing swelling and eventual blindness.
The current gold standard for treating this condition involves injecting anti-VEGF (Vascular Endothelial Growth Factor) medications directly into the vitreous humor of the eye. While effective, these procedures are invasive and require frequent clinic visits, creating significant financial and psychological burdens for patients, particularly those in underserved regions.
The Science of Simplification: From 123 to 3 Amino Acids
The breakthrough developed at the Institute of Neurobiology (INB) is the result of decades of study within the Molecular Endocrinology Laboratory, led by Dr. Carmen Clapp. The team focused on vasoinhibin, a natural molecule capable of inhibiting the growth of abnormal blood vessels.
The primary challenge with using such molecules in the eye has always been delivery. Most potent proteins are too large to penetrate the cornea, which is why doctors must inject them surgically. However, the research team, including investigator Juan Pablo Robles and lead author Magdalena Zamora, discovered a critical “tipping point” in the molecule’s structure.
They identified that the biological activity of vasoinhibin—its ability to stop abnormal vessel growth—is not spread across its entire 123-amino acid chain. Instead, the active power is concentrated in just three specific amino acids. By isolating this minimal active sequence, the researchers were able to design a much smaller, simpler drug candidate that can be administered as a topical drop rather than a needle.
These findings were recently published in the Journal of Biological Chemistry, where the study received editorial recognition for its potential to shift the clinical landscape of retinal care.
Beyond VEGF: A More Comprehensive Approach
Most existing retinal therapies target a single protein: VEGF. While blocking VEGF is effective, the eye’s biological environment is complex, and other molecules often step in to drive angiogenesis even when VEGF is suppressed. This is why some patients stop responding to current injections over time.
The UNAM-developed therapy is designed to be more versatile. Because it is based on the natural properties of vasoinhibin, it does not only block VEGF but similarly inhibits other related molecules that contribute to the disease. This multi-pronged attack could potentially lead to higher efficacy and longer-lasting results compared to single-target therapies.
The implications for public health are particularly acute in Mexico, where diabetic retinopathy is a primary cause of visual impairment among adults in their most productive working years. A non-invasive treatment would not only improve the quality of life for patients but also reduce the immense strain on national healthcare systems.
Comparing Treatment Modalities
| Feature | Current Standard (Injections) | UNAM Proposal (Drops) |
|---|---|---|
| Administration | Intraocular Injection | Ophthalmic Drops |
| Invasiveness | High (Surgical) | Non-invasive (Topical) |
| Target | Primarily VEGF | VEGF and related molecules |
| Patient Burden | High (Frequent clinic visits) | Low (Self-administered) |
| Cost | Expensive per dose | Potentially lower production cost |
The Path to Clinical Application
While the laboratory results are promising, the project is now moving toward the most critical phase: validation in humans. The transition from basic science—studying how molecules behave in a lab—to clinical application is a rigorous process that requires stringent safety and efficacy trials.
The goal is to offer a viable alternative for various retinal diseases, not just those caused by diabetes. If the drops prove successful in human trials, they could democratize access to sight-saving medicine, removing the barriers of cost and surgical fear that prevent many patients from seeking timely treatment.
This development highlights the importance of long-term investment in basic research. The “breakthrough” of the three amino acids was only possible because of years of foundational work in molecular endocrinology, proving that deep scientific inquiry often yields the most practical medical solutions.
Disclaimer: This article is provided for informational purposes only and does not constitute medical advice. Patients experiencing vision changes or managing diabetes should consult a board-certified ophthalmologist or endocrinologist for diagnosis, and treatment.
The next confirmed milestone for the research team is the initiation of human validation trials to determine the optimal dosage and safety profile of the drops. Further updates are expected as the project moves through regulatory review stages.
Do you believe non-invasive treatments will revolutionize chronic disease management? Share your thoughts in the comments or share this story with someone affected by diabetic retinopathy.
